• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure

byNeel MistryandTeddy Guo
September 13, 2022
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection fractions.

2. The number needed to treat (NNT) to prevent a first hospitalization was 28 in patients receiving SGLT-2 inhibitors.

Evidence Rating Level: 1 (Excellent)

Study Rundown: SGLT-2 inhibitors have been used to manage heart failure patients with reduced ejection fractions. However, their efficacy in patients with mixed or preserved ejection fraction remains unclear. The current study includes patients from two large-scale trials, DELIVER and EMPEROR-Preserved, with mildly reduced or preserved ejection fraction. This meta-analysis aimed to assess the safety and efficacy of SGLT-2 inhibitors on heart failure-related hospitalization and cardiovascular mortality. Primary outcome was the time to admission or cardiovascular death, while key secondary outcomes included worsening heart failure event and all-cause mortality. According to study results, SGLT-2 inhibitors decreased the rate of cardiovascular mortality and heart failure-related hospitalization. The benefits seen with SGLT-2 inhibitors was demonstrated across various levels of ejection fractions. A major strength of this study was that it aggregated data from five well-conducted randomized controlled trials, thus adding to its validity.

Click to read the study in The Lancet

Relevant Reading: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

RELATED REPORTS

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

In-depth [meta-analysis]: This study comprised of patients from 5 large-scale trials (DAPA-HF, DELIVER, EMPEROR-Reduced, EMPEROR-Preserved, and SOLOIST-WHF) conducted between 2017 and 2021. Each of the included trials compared an SGLT-2 inhibitor (dapagliflozin, empagliflozin, and sotagliflozin) to placebo control. Included were patients with reduced (HFrEF) and preserved (HFpEF) ejection fraction, and those admitted for worsening heart failure. The primary composite outcome (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.73-0.87) was significantly reduced in patients receiving SGLT-2 inhibitors. The benefits of SGLT-2 inhibitors were further demonstrated with improvements in first admission for heart failure (HR 0.74, 95% CI 0.67-0.83) and cardiovascular death (HR 0.88, 95% CI 0.77-1.00) among patients with HFpEF (n=12251). This was also the case for patients in all 5 trials, regardless of ejection fraction: hospitalization for health failure (HR 0.72, 95% CI 0.67-0.78), cardiovascular death (HR 0.87, 95% CI 0.79-0.95), and all-cause mortality (HR 0.92, 95% CI 0.86-0.99). Treatment with SGLT-2 inhibitors reduced the risk of first hospitalization for heart failure with a NNT of 28. Overall, findings from this study recommend the routine use of SGLT-2 inhibitors in patients with heart failure with both reduced and preserved ejection fraction.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular mortalitydapagliflozindiabetesempagliflozinheart failurehfpefHFpEF (heart failure with preserved ejection fractionhfrefHFrEF (heart failure with reduced ejection fraction)SGLT-2 inhibitorsSotagliflozin
Previous Post

Early rhythm control for atrial fibrillation reduces the risk of adverse cardiovascular events

Next Post

Psychological stress prior to infection may increase risk of long COVID

RelatedReports

Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Pediatric DKA associated with recent acute care visits
Chronic Disease

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

July 3, 2025
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

July 2, 2025
Next Post

Psychological stress prior to infection may increase risk of long COVID

#VisualAbstract: Functional testing nonsuperior to routine care for percutaneous coronary intervention patients

#VisualAbstract: Functional testing nonsuperior to routine care for percutaneous coronary intervention patients

Large proportion of late preterm infants and older admitted to the NICU

Children with inborn errors of metabolism have increased risk of long-term mortality

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abridge drafts pediatric notes so physicians stay with the kids, not the keyboard
  • AAV gene therapy shows durable benefit in hemophilia B
  • Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.